Chronic Lymphocytic Leukemia

The triplet regimen acalabrutinib, venetoclax, and obinutuzumab in the frontline chronic lymphocytic leukemia setting was highly active and well tolerated demonstrating durable responses.

Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.

Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.

An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, John N. Allan, MD, discussed the data supporting the use of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.

Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .

Jennifer R. Brown, MD, PhD, discusses the mechanism of action of zanubrutinib and how it differs from other Bruton’s tyrosine kinase inhibitors.

Topline results from the phase 2 TRANSCEND CLL 004 trial hint that lisocabtagene maraleucel may be active in relapsed or refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022.

Zanubrutinib has been granted FDA approval for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Alexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.

Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.

In an interview with Targeted Oncology, Thomas Kipps, MD, PhD, explained the new treatment options and challenges being faced in the chronic lymphocytic leukemia space.

Thomas James Kipps, MD, PhD, discusses the role of later generation and newer generation burton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, provides an overview on the recent updates and research in the chronic lymphocytic leukemia space.

In an interview with Targeted Oncology, Brian T. Hill, MD, PhD, discussed making treatment decisions for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Alexey Danilov, MD, PhD, discusses some targeted therapies being investigated in the relapsed/refractory chronic lymphocytic leukemia space.

Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.

William Wierda, MD, PhD, explored the emergence of small molecule-inhibitor targeted therapies during the “Workup of CLL in the Era of Small Molecules,” presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Alexey Danilov, MD, PhD, discusses the current treatment landscape for chronic lymphocytic leukemia and how it has evolved.

In an interview with Targeted Oncology, Alexey Danilov, MD, PhD, delved into the latest treatment strategies and approvals investigated for patients with chronic lymphocytic leukemia.

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.